TIKOMED Announce Start of ALS Study at Sahlgrenska University Hospital

Press Release (ePRNews.com) - VIKEN, Sweden - Aug 14, 2018 - TIKOMED, a specialty pharmaceutical company focused on developing therapeutics for treating acute and degenerative neurological and ophthalmic diseases, is delighted to announce that the company today has started its clinical trial (Phase 2a) in Amyotrophic Lateral Sclerosis (ALS) at Sahlgrenska University Hospital.

Anders Svenson M.D., Chief Medical Officer of TIKOMED, commented, “Today, we present an important milestone, with the start of our first phase 2a clinical trial in ALS at Sahlgrenska University Hospital. We are excited and hope ILB’s unique mechanism of action, triggering self-repair and protection will bring new hope to both patients and caregivers suffering from ALS.

Anders Kristensson, Chief Executive Officer of TIKOMED, commented, “Today there is no cure for ALS and the available drug treatment consists of medicine slowing the progression. We hope our ILB drug will prove to be a game changer in ALS and for those patients and caregivers impacted by this terrible disease.”

The study is performed at and in collaboration with Sahlgrenska University Hospital, Gothenburg, Sweden. Assoc. Professor Lennart Persson, an expert in ALS, will be principal investigator.15 patients will be treated with ILB during a 4-week period.

Source : TIKOMED AB
SHARE :  
Business Info :
TikoMed AB

You may also like this  

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or Signup using Email

Already have an account ? Login

Reset Password

Already have an account ? Login

DISCLAIMER

If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/ services/ business mentioned and hereby disclaims any content contained in this press release.